<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Sci</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Sci</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1349-7006</journal-id><journal-id journal-id-type="publisher-id">CAS</journal-id><journal-title-group><journal-title>Cancer Science</journal-title></journal-title-group><issn pub-type="ppub">1347-9032</issn><issn pub-type="epub">1349-7006</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29478257</article-id><article-id pub-id-type="pmc">5980148</article-id><article-id pub-id-type="doi">10.1111/cas.13550</article-id><article-id pub-id-type="publisher-id">CAS13550</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma</article-title><alt-title alt-title-type="left-running-head">IIDA et&#x000a0;al.</alt-title></title-group><contrib-group><contrib id="cas13550-cr-0001" contrib-type="author" corresp="yes"><name><surname>Iida</surname><given-names>Shinsuke</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4951-960X</contrib-id><address><email>iida@med.nagoya-cu.ac.jp</email></address><xref ref-type="aff" rid="cas13550-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cas13550-cr-0002" contrib-type="author"><name><surname>Wakabayashi</surname><given-names>Masashi</given-names></name><xref ref-type="aff" rid="cas13550-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cas13550-cr-0003" contrib-type="author"><name><surname>Tsukasaki</surname><given-names>Kunihiro</given-names></name><xref ref-type="aff" rid="cas13550-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="cas13550-cr-0004" contrib-type="author"><name><surname>Miyamoto</surname><given-names>Kenichi</given-names></name><xref ref-type="aff" rid="cas13550-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cas13550-cr-0005" contrib-type="author"><name><surname>Maruyama</surname><given-names>Dai</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0654-6920</contrib-id><xref ref-type="aff" rid="cas13550-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="cas13550-cr-0006" contrib-type="author"><name><surname>Yamamoto</surname><given-names>Kazuhito</given-names></name><xref ref-type="aff" rid="cas13550-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="cas13550-cr-0007" contrib-type="author"><name><surname>Takatsuka</surname><given-names>Yoshifusa</given-names></name><xref ref-type="aff" rid="cas13550-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="cas13550-cr-0008" contrib-type="author"><name><surname>Kusumoto</surname><given-names>Shigeru</given-names></name><xref ref-type="aff" rid="cas13550-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cas13550-cr-0009" contrib-type="author"><name><surname>Kuroda</surname><given-names>Junya</given-names></name><xref ref-type="aff" rid="cas13550-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="cas13550-cr-0010" contrib-type="author"><name><surname>Ando</surname><given-names>Kiyoshi</given-names></name><xref ref-type="aff" rid="cas13550-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="cas13550-cr-0011" contrib-type="author"><name><surname>Kikukawa</surname><given-names>Yoshitaka</given-names></name><xref ref-type="aff" rid="cas13550-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="cas13550-cr-0012" contrib-type="author"><name><surname>Masaki</surname><given-names>Yasufumi</given-names></name><xref ref-type="aff" rid="cas13550-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="cas13550-cr-0013" contrib-type="author"><name><surname>Kobayashi</surname><given-names>Miki</given-names></name><xref ref-type="aff" rid="cas13550-aff-0011">
<sup>11</sup>
</xref></contrib><contrib id="cas13550-cr-0014" contrib-type="author"><name><surname>Hanamura</surname><given-names>Ichiro</given-names></name><xref ref-type="aff" rid="cas13550-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="cas13550-cr-0015" contrib-type="author"><name><surname>Asai</surname><given-names>Hiroaki</given-names></name><xref ref-type="aff" rid="cas13550-aff-0013">
<sup>13</sup>
</xref></contrib><contrib id="cas13550-cr-0016" contrib-type="author"><name><surname>Nagai</surname><given-names>Hirokazu</given-names></name><xref ref-type="aff" rid="cas13550-aff-0014">
<sup>14</sup>
</xref></contrib><contrib id="cas13550-cr-0017" contrib-type="author"><name><surname>Shimada</surname><given-names>Kazuyuki</given-names></name><xref ref-type="aff" rid="cas13550-aff-0015">
<sup>15</sup>
</xref></contrib><contrib id="cas13550-cr-0018" contrib-type="author"><name><surname>Tsukamoto</surname><given-names>Norifumi</given-names></name><xref ref-type="aff" rid="cas13550-aff-0016">
<sup>16</sup>
</xref></contrib><contrib id="cas13550-cr-0019" contrib-type="author"><name><surname>Inoue</surname><given-names>Yoshiko</given-names></name><xref ref-type="aff" rid="cas13550-aff-0017">
<sup>17</sup>
</xref></contrib><contrib id="cas13550-cr-0020" contrib-type="author"><name><surname>Tobinai</surname><given-names>Kensei</given-names></name><xref ref-type="aff" rid="cas13550-aff-0004">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="cas13550-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Hematology and Oncology</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>Nagoya City University Hospital</institution>
<named-content content-type="city">Nagoya</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">JCOG Data Center/Operations Office</named-content>
<institution>National Cancer Center</institution>
<named-content content-type="city">Tokyo</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Hematology</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>National Cancer Center Hospital East</institution>
<named-content content-type="city">Kashiwa</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Hematology</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>National Cancer Center Hospital</institution>
<named-content content-type="city">Tokyo</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Department of Hematology and Cell Therapy</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>Aichi Cancer Center Hospital</institution>
<named-content content-type="city">Nagoya</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Department of Hematology</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>Imamura General Hospital</institution>
<named-content content-type="city">Kagoshima</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">Division of Hematology and Oncology</named-content>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>Kyoto Prefectural University</institution>
<named-content content-type="city">Kyoto</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0008">
<label><sup>8</sup></label>
<named-content content-type="organisation-division">Department of Hematology and Oncology</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>Tokai University of School of Medicine</institution>
<named-content content-type="city">Isehara</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0009">
<label><sup>9</sup></label>
<named-content content-type="organisation-division">Department of Hematology</named-content>
<named-content content-type="organisation-division">Rheumatology and Infectious Diseases</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>Kumamoto University Hospital</institution>
<named-content content-type="city">Kumamoto</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0010">
<label><sup>10</sup></label>
<named-content content-type="organisation-division">Department of Hematology and Immunology</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>Kanazawa Medical University</institution>
<named-content content-type="city">Kahoku</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0011">
<label><sup>11</sup></label>
<named-content content-type="organisation-division">Department of Hematology and Oncology</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>Japanese Red Cross Nagoya Daini Hospital</institution>
<named-content content-type="city">Nagoya</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0012">
<label><sup>12</sup></label>
<named-content content-type="organisation-division">Division of Hematology</named-content>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>Aichi Medical University</institution>
<named-content content-type="city">Nagakute</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0013">
<label><sup>13</sup></label>
<named-content content-type="organisation-division">First Department of Internal Medicine</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>Ehime University Hospital</institution>
<named-content content-type="city">Toon</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0014">
<label><sup>14</sup></label>
<named-content content-type="organisation-division">Department of Hematology</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>National Hospital Organization Nagoya Medical Center</institution>
<named-content content-type="city">Nagoya</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0015">
<label><sup>15</sup></label>
<named-content content-type="organisation-division">Department of Hematology and Oncology</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>Nagoya University Graduate School of Medicine</institution>
<named-content content-type="city">Nagoya</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0016">
<label><sup>16</sup></label>
<named-content content-type="organisation-division">Oncology Center</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>Gunma University Hospital</institution>
<named-content content-type="city">Maebashi</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas13550-aff-0017">
<label><sup>17</sup></label>
<named-content content-type="organisation-division">Department of Hematology</named-content>
<institution>Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG&#x02010;LSG)</institution>
<institution>National Hospital Organization Kumamoto Medical Center</institution>
<named-content content-type="city">Kumamoto</named-content>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Shinsuke Iida, Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.<break/>
Email: <email>iida@med.nagoya-cu.ac.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2018</year></pub-date><volume>109</volume><issue>5</issue><issue-id pub-id-type="doi">10.1111/cas.2018.109.issue-5</issue-id><fpage>1552</fpage><lpage>1561</lpage><history><date date-type="received"><day>13</day><month>10</month><year>2017</year></date><date date-type="rev-recd"><day>31</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>19</day><month>2</month><year>2018</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 Japanese Cancer Association <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2018 The Authors. <italic>Cancer Science</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japanese Cancer Association.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CAS-109-1552.pdf"/><abstract id="cas13550-abs-0001"><p>A randomized phase <styled-content style="fixed-case">II</styled-content> selection design study (<styled-content style="fixed-case">JCOG</styled-content>0904) was carried out to evaluate the more promising regimen between bortezomib (Bor) plus dexamethasone (Dex; <styled-content style="fixed-case">BD</styled-content>) and thalidomide (Thal) plus Dex (<styled-content style="fixed-case">TD</styled-content>) in Bor and Thal&#x02010;na&#x000ef;ve patients with relapsed or refractory multiple myeloma (<styled-content style="fixed-case">RRMM</styled-content>). Patients &#x02265;20 and &#x0003c;80&#x000a0;years old with a documented diagnosis of symptomatic multiple myeloma (<styled-content style="fixed-case">MM</styled-content>) who received one or more prior therapies were randomized to receive <styled-content style="fixed-case">BD</styled-content> (Bor 1.3&#x000a0;mg/m<sup>2</sup>) or <styled-content style="fixed-case">TD</styled-content> (Thal 200&#x000a0;mg/d). In both arms, 8 cycles of induction (3&#x02010;week cycle) were followed by maintenance phase (5&#x02010;week cycle) until disease progression, unacceptable toxicity, or patient refusal. The primary end&#x02010;point was 1&#x02010;year progression&#x02010;free survival (<styled-content style="fixed-case">PFS</styled-content>). Forty&#x02010;four patients were randomized and assigned to receive <styled-content style="fixed-case">BD</styled-content> and <styled-content style="fixed-case">TD</styled-content> (n&#x000a0;=&#x000a0;22, each group). At a median follow&#x02010;up of 34.3&#x000a0;months, the 1&#x02010;year <styled-content style="fixed-case">PFS</styled-content> in the <styled-content style="fixed-case">BD</styled-content> and <styled-content style="fixed-case">TD</styled-content> arms were 45.5% (95% confidence interval (<styled-content style="fixed-case">CI</styled-content>), 24.4%&#x02010;64.3%) and 31.8% (95% <styled-content style="fixed-case">CI</styled-content>, 14.2%&#x02010;51.1%), respectively, and the overall response rates were 77.3% and 40.9%, respectively. The 3&#x02010;year overall survival (<styled-content style="fixed-case">OS</styled-content>) was 70.0% (95% <styled-content style="fixed-case">CI</styled-content>, 44.9%&#x02010;85.4%) in the <styled-content style="fixed-case">BD</styled-content>, and 48.8% (95% <styled-content style="fixed-case">CI</styled-content>, 25.1%&#x02010;69.0%) in the <styled-content style="fixed-case">TD</styled-content> arm. Among grade 3/4 adverse events, thrombocytopenia (54.5% vs 0.0%) and sensory peripheral neuropathy (22.7% vs 9.1%) were more frequent in <styled-content style="fixed-case">BD</styled-content> when compared with the <styled-content style="fixed-case">TD</styled-content> arm. Patients treated with <styled-content style="fixed-case">BD</styled-content> had better outcomes than those treated with <styled-content style="fixed-case">TD</styled-content> with regard to 1&#x02010;year <styled-content style="fixed-case">PFS</styled-content> and 3&#x02010;year <styled-content style="fixed-case">OS</styled-content>. Thus, <styled-content style="fixed-case">BD</styled-content> was prioritized over <styled-content style="fixed-case">TD</styled-content> for further investigations in Bor and Thal&#x02010;na&#x000ef;ve <styled-content style="fixed-case">RRMM</styled-content> patients. (Clinical trial registration no. <styled-content style="fixed-case">UMIN</styled-content>000003135.)</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cas13550-kwd-0001">bortezomib</kwd><kwd id="cas13550-kwd-0002">dexamethasone</kwd><kwd id="cas13550-kwd-0003">randomized phase <styled-content style="fixed-case">II</styled-content> study</kwd><kwd id="cas13550-kwd-0004">relapsed or refractory multiple myeloma</kwd><kwd id="cas13550-kwd-0005">thalidomide</kwd></kwd-group><funding-group><award-group><funding-source>National Cancer Center Research and Development Fund</funding-source><award-id>26&#x02010;A&#x02010;4</award-id><award-id>29&#x02010;A&#x02010;3</award-id></award-group><award-group><funding-source>Ministry of Health, Labor and Welfare of Japan</funding-source><award-id>201119011C</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="10"/><word-count count="8646"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>cas13550</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.0 mode:remove_FC converted:31.05.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="cas13550-cit-1001">
<string-name>
<surname>Iida</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wakabayashi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tsukasaki</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma</article-title>. <source xml:lang="en">Cancer Sci</source>. <year>2018</year>;<volume>109</volume>:<fpage>1552</fpage>&#x02013;<lpage>1561</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/cas.13550">https://doi.org/10.1111/cas.13550</ext-link>
</mixed-citation>
</p><fn-group id="cas13550-ntgp-0001"><fn fn-type="funding" id="cas13550-note-1001"><p>
<bold>Funding information</bold>
</p><p>National Cancer Center Research and Development Fund (26&#x02010;A&#x02010;4, 29&#x02010;A&#x02010;3), Ministry of Health, Labor and Welfare of Japan (201119011C).</p></fn></fn-group></notes></front><body><def-list list-content="abbreviations" id="cas13550-dl-0001"><title>Abbreviations</title><def-item><term>AE</term><def><p>adverse event</p></def></def-item><def-item><term>ALT</term><def><p>alanine aminotransferase</p></def></def-item><def-item><term>ASCT</term><def><p>autologous stem cell transplantation</p></def></def-item><def-item><term>AST</term><def><p>aspartate aminotransferase</p></def></def-item><def-item><term>BD</term><def><p>bortezomib&#x000a0;+&#x000a0;dexamethasone</p></def></def-item><def-item><term>CI</term><def><p>confidence interval</p></def></def-item><def-item><term>CR</term><def><p>complete response</p></def></def-item><def-item><term>Dex</term><def><p>dexamethasone</p></def></def-item><def-item><term>HBs</term><def><p>hepatitis B virus surface</p></def></def-item><def-item><term>HBV</term><def><p>hepatitis B virus</p></def></def-item><def-item><term>HDD</term><def><p>high&#x02010;dose dexamethasone</p></def></def-item><def-item><term>HR</term><def><p>hazard ratio</p></def></def-item><def-item><term>JCOG</term><def><p>Japan Clinical Oncology Group</p></def></def-item><def-item><term>LD</term><def><p>lenalidomide&#x02009;+&#x02009;dexamethasone</p></def></def-item><def-item><term>Ld</term><def><p>lenalidomide + low&#x02010;dose dexamethasone</p></def></def-item><def-item><term>MM</term><def><p>multiple myeloma</p></def></def-item><def-item><term>NMSG</term><def><p>Nordic Myeloma Study Group</p></def></def-item><def-item><term>ORR</term><def><p>overall response rate</p></def></def-item><def-item><term>OS</term><def><p>overall survival</p></def></def-item><def-item><term>PFS</term><def><p>progression&#x02010;free survival</p></def></def-item><def-item><term>PI</term><def><p>proteasome inhibitor</p></def></def-item><def-item><term>PN</term><def><p>peripheral neuropathy</p></def></def-item><def-item><term>RRMM</term><def><p>relapsed or refractory multiple myeloma</p></def></def-item><def-item><term>SD</term><def><p>stable disease</p></def></def-item><def-item><term>TD</term><def><p>thalidomide + dexamethasone</p></def></def-item></def-list><sec id="cas13550-sec-0001"><label>1</label><title>INTRODUCTION</title><p>The introduction of PI and immunomodulatory imide drugs into clinical practice has remarkably prolonged the OS of patients with MM.<xref rid="cas13550-bib-0001" ref-type="ref">1</xref>, <xref rid="cas13550-bib-0002" ref-type="ref">2</xref>
</p><p>In October 2006, the first&#x02010;generation PI, bortezomib, was approved for use in patients with RRMM in Japan based on the results of a phase I/II study carried out in the country.<xref rid="cas13550-bib-0003" ref-type="ref">3</xref> In the phase I part, the patients received i.v. bolus injections of bortezomib (0.7, 1.0, or 1.3&#x000a0;mg/m<sup>2</sup>) on days 1, 4, 8, and 11 every 21&#x000a0;days. A maximum dose of 1.3&#x000a0;mg/m<sup>2</sup> was determined as the recommended dose. The ORR was 30.0% (10/33) with a 95% CI of 16%&#x02010;49%, which was similar (ORR 38.0%) to that observed in patients assigned to the bortezomib arm in another international phase III study (APEX) comparing bortezomib with HDD in patients with relapsed MM.<xref rid="cas13550-bib-0003" ref-type="ref">3</xref>, <xref rid="cas13550-bib-0004" ref-type="ref">4</xref> In APEX, the primary end&#x02010;point was PFS, and it was longer in the patients treated with bortezomib than those with HDD (median PFS, 6.22 vs 3.49&#x000a0;months; HR, 0.55; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;.001). The safety signal was also similar between the Japanese phase I/II studies and the bortezomib arm of APEX. The addition of Dex to bortezomib (BD) improved the ORR in 21.8% (22/101) of the patients, whose best response was SD or progressive disease with bortezomib alone in two phase II studies, and reduced the occurrence of AEs, including gastrointestinal symptoms, rash, and fever. Thus, the BD regimen became the standard of care for RRMM.<xref rid="cas13550-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13550-bib-0006" ref-type="ref">6</xref>
</p><p>Subsequently, based on a Japanese phase II study, thalidomide was approved as a single agent in Japan for patients with RRMM in October 2008.<xref rid="cas13550-bib-0007" ref-type="ref">7</xref> It was given orally at a dosage of 100&#x000a0;mg/d before sleep, and gradually increased up to 400&#x000a0;mg/d. The ORR in this study was 14.7% (5/34) and a 2&#x02010;year PFS of 44.0%.<xref rid="cas13550-bib-0007" ref-type="ref">7</xref> Thalidomide alone showed an ORR of 29.4% in a systematic review of 1674 cases,<xref rid="cas13550-bib-0008" ref-type="ref">8</xref> whereas the addition of Dex to thalidomide (TD) showed a much higher ORR of 46.3% (95% CI, 42%&#x02010;51%) in another systematic review of 451 cases enrolled in 12 phase II studies.<xref rid="cas13550-bib-0009" ref-type="ref">9</xref>, <xref rid="cas13550-bib-0010" ref-type="ref">10</xref>, <xref rid="cas13550-bib-0011" ref-type="ref">11</xref> The median event&#x02010;free survival with a weighted median value in 6 studies was 8&#x000a0;months, although it varied from 3.9 to 12&#x000a0;months. Accordingly, the TD regimen is recognized as another standard of care for the patients with RRMM.</p><p>Subsequently, in June 2010, lenalidomide, the first thalidomide derivative, was approved for use in combination with HDD in patients with RRMM based on two international phase III studies called MM009 and MM010, both of which reported superior outcomes of lenalidomide plus Dex (LD) when compared with HDD alone,<xref rid="cas13550-bib-0012" ref-type="ref">12</xref>, <xref rid="cas13550-bib-0013" ref-type="ref">13</xref> and with the results of the Japanese phase I study.<xref rid="cas13550-bib-0014" ref-type="ref">14</xref> The ORRs of LD therapy in patients with RRMM were 59.4% and 60.2% in MM009 and MM010, respectively, with a median PFS of 11.1&#x000a0;months.</p><p>Currently, doublet regimens consisting of a novel agent and Dex, such as BD, TD, and LD or Ld, are given in a sequential manner, because they are convenient to use in the outpatient setting. More recent studies on triplet regimens including the third agents such as mAbs<xref rid="cas13550-bib-0015" ref-type="ref">15</xref>, <xref rid="cas13550-bib-0016" ref-type="ref">16</xref>, <xref rid="cas13550-bib-0017" ref-type="ref">17</xref> or histone deacetylase inhibitors<xref rid="cas13550-bib-0018" ref-type="ref">18</xref> and a combination of PI, immunomodulatory imide drugs, and Dex<xref rid="cas13550-bib-0019" ref-type="ref">19</xref>, <xref rid="cas13550-bib-0020" ref-type="ref">20</xref>, <xref rid="cas13550-bib-0021" ref-type="ref">21</xref> have shown higher efficacy than doublet regimens. For instance, median PFS of Ld in combination with either elotuzumab, ixazomib, or carfilzomib were reported to be 19.4, 20.6, and 26.3&#x000a0;months, respectively.<xref rid="cas13550-bib-0015" ref-type="ref">15</xref>, <xref rid="cas13550-bib-0019" ref-type="ref">19</xref>, <xref rid="cas13550-bib-0020" ref-type="ref">20</xref> In addition, the median PFS of BD in combination with panobinostat, a histone deacetylase inhibitor, was reported to be 12.0&#x000a0;months.<xref rid="cas13550-bib-0018" ref-type="ref">18</xref> However, increase in the number of AEs and the cost of the triplet regimens may hamper their use. Therefore, the use of doublet regimens is still important in our clinical practice.</p><p>Nevertheless, an optimal doublet regimen for novel&#x02010;agent&#x02010;na&#x000ef;ve patients with RRMM that might help in achieving long&#x02010;term survival has not been identified so far. Therefore, the present study aimed to select a more promising regimen with BD and TD in RRMM patients who had never been treated with the 2 agents. The study began in 2009, when lenalidomide was not yet available in Japan.</p></sec><sec id="cas13550-sec-0002"><label>2</label><title>MATERIALS AND METHODS</title><sec id="cas13550-sec-0003"><label>2.1</label><title>Eligibility criteria</title><p>This open&#x02010;label randomized phase II multicenter trial (JCOG0904, UMIN000003135) was undertaken in 41 hospitals in Japan. The study protocol was approved by the Protocol Review Committee of JCOG and the institutional review board of each participating hospital. Written informed consent was obtained from all patients before enrollment, in accordance with the policies of JCOG and Japanese ethical guidelines.</p><p>Eligibility criteria were as follows: (i) RRMM after receiving at least one prior therapy with a documented diagnosis of symptomatic MM according to International Myeloma Working Group criteria;<xref rid="cas13550-bib-0022" ref-type="ref">22</xref> (ii) age 20&#x02010;79&#x000a0;years; (iii) na&#x000ef;ve to bortezomib and thalidomide; (iv) an ECOG performance status of &#x02264;2 or 3 due to osteolytic lesions; and (v) measurable paraprotein levels defined as serum monoclonal immunoglobulin concentrations of at least 1.0&#x000a0;g/dL IgG, or at least 0.5&#x000a0;g/dL absolute serum concentration of IgA/IgD, or urinary excretion of at least 0.2&#x000a0;g paraprotein per 24&#x000a0;h. Allowable blood count values and laboratory data were as follows: absolute neutrophil count &#x02265;1200/mm<sup>3</sup>; platelet count &#x02265;6&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup>/mm<sup>3</sup>; hemoglobin level &#x02265;7.0&#x000a0;g/dL; AST/ALT &#x02264;100&#x000a0;IU/L; total bilirubin &#x02264;1.8&#x000a0;mg/dL; serum creatinine &#x02264;2.5&#x000a0;mg/dL; corrected serum calcium &#x02264;12.5&#x000a0;mg/dL; PaO<sub>2</sub> &#x02265;70 Torr; and cardiac ejection fraction &#x02265;50%. Other inclusion criteria were the absence of cardiac or gastrointestinal amyloidosis and secondary plasma cell leukemia.</p><p>Major exclusion criteria were the presence of the following complications or patient status: (i) synchronous or metachronous malignancy; (ii) active infection; (iii) psychological disturbance; (iv) insulin&#x02010;dependent or uncontrollable diabetes mellitus; (v) uncontrollable hypertension; (vi) interstitial pneumonitis; (vii) PN &#x02265;grade 2; (viii) neuropathic pain &#x02265;grade 1; and (ix) positivity for HBs antigen, detectable serum HBV&#x02010;DNA, anti&#x02010;hepatitis C virus, or anti&#x02010;HIV.</p></sec><sec id="cas13550-sec-0004"><label>2.2</label><title>Study design</title><sec id="cas13550-sec-0005"><label>2.2.1</label><title>Randomization and monitoring</title><p>The patients were randomly assigned (1:1) to receive the BD or TD regimen by the minimization method with a biased coin assignment according to the institution, the number of prior therapies (1 or &#x02265;2), and a history of ASCT. Randomization was carried out at the JCOG Data Center based on requests from the participating institutions by telephone or fax. All patient information was collected and managed at the JCOG Data Center. The monitoring reports were submitted to and reviewed by the Data and Safety Monitoring Committee of JCOG semi&#x02010;annually.</p></sec><sec id="cas13550-sec-0006"><label>2.2.2</label><title>Treatment according to randomization</title><p>In the BD arm, bortezomib (1.3&#x000a0;mg/m<sup>2</sup>) was given i.v. or s.c. on days 1, 4, 8, and 11 of a 3&#x02010;week cycle for 8 cycles, with 20&#x000a0;mg Dex given orally on days 1&#x02010;2, 4&#x02010;5, 8&#x02010;9, and 11&#x02010;12 for the first 2 cycles, and on days 1&#x02010;2 and 4&#x02010;5 during cycles 3&#x02010;8. This was followed by a maintenance phase consisting of bortezomib on days 1, 8, 15, and 22 of a 5&#x02010;week cycle with Dex given on days 1&#x02010;4 until disease progression, unacceptable toxicity, or patient refusal. Bortezomib s.c. injection was allowed to reduce PN by the protocol amendments in November 2012. In the TD arm, thalidomide was given orally at a dose of 100&#x000a0;mg once daily and escalated to 200&#x000a0;mg on day 29 if tolerated with 20&#x000a0;mg Dex on days 1&#x02010;4 and 8&#x02010;11 of a 3&#x02010;week cycle for the first 2 cycles and on days 1&#x02010;4 during cycles 3&#x02010;8. This was followed by a daily dose of thalidomide with 20&#x000a0;mg Dex on days 1&#x02010;4 of a 5&#x02010;week cycle as maintenance phase. Thus, the total amount of Dex given in each cycle was exactly the same between BD and TD regimens. In both arms, each cycle was initiated if the patient fulfilled the following criteria: absolute neutrophil count &#x02265;1000/mm<sup>3</sup>; platelet count &#x02265;5&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup>/mm<sup>3</sup>; AST and ALT&#x000a0;&#x0003c;100&#x000a0;IU/L; and the absence of PN &#x02265;grade 3, PN &#x02265;grade 1 with neuropathic pain, diarrhea &#x02265;grade 2 within 24&#x000a0;h, and infection &#x02265;grade 2. Dose reduction, skip, or delay were made as outlined in Doc. <xref rid="cas13550-sup-0006" ref-type="supplementary-material">S1</xref>. The treatment protocol was terminated when the subsequent cycle was delayed beyond 21&#x000a0;days due to the AEs other than neurotoxicity or postponed beyond 280&#x000a0;days due to neurotoxicity.</p></sec><sec id="cas13550-sec-0007"><label>2.2.3</label><title>Concomitant medication</title><p>Acyclovir prophylaxis was recommended for patients assigned in the BD arm to prevent the development of herpes zoster,<xref rid="cas13550-bib-0023" ref-type="ref">23</xref> whereas anti&#x02010;thrombotic prophylaxis such as low&#x02010;dose aspirin or warfarin was recommended for the patients assigned to the TD arm.<xref rid="cas13550-bib-0024" ref-type="ref">24</xref> The concomitant use of zoledronic acid or denosumab was permitted for patients carrying osteolytic lesions. In patients with resolved HBV infection defined as seronegative for HBs antigen and seropositive for anti&#x02010;hepatitis B core or anti&#x02010;HBs antibodies, pre&#x02010;emptive antiviral therapy using entecavir was carried out to prevent HBV&#x02010;related hepatitis, guided by monthly HBV&#x02010;DNA monitoring.<xref rid="cas13550-bib-0025" ref-type="ref">25</xref>
</p></sec></sec><sec id="cas13550-sec-0008"><label>2.3</label><title>Outcomes</title><p>The primary end&#x02010;point was a 1&#x02010;year PFS. Secondary end&#x02010;points included incidence of AEs, incidence of serious AEs, best ORR, PFS, and OS. Progression&#x02010;free survival was calculated from the date of registration until the date of disease progression, death from any cause, or until the date the patient was confirmed to be progression&#x02010;free. Overall survival was calculated from the date of registration until the date of death from any cause or the last date of follow&#x02010;up. Toxicities were evaluated according to the NCI's Common Terminology Criteria for Adverse Events version 3.0.<xref rid="cas13550-bib-0026" ref-type="ref">26</xref> Treatment response was assessed according to the international uniform response criteria for MM defined by the International Myeloma Working Group.<xref rid="cas13550-bib-0027" ref-type="ref">27</xref> The overall response included stringent complete response, complete response (CR), very good partial response, and partial response.</p></sec><sec id="cas13550-sec-0009"><label>2.4</label><title>Statistical methods</title><p>This was a randomized phase II selection design study. The regimen that shows a higher point estimate of the proportion of 1&#x02010;year PFS is considered more promising. All randomized patients were analyzed on an intention&#x02010;to treat basis. Originally, the planned sample size was set at 80 patients to select the better arm in a 1&#x02010;year PFS of 55% to the worst arm in that of 45% with a correct selection probability of 80%, according to Simon's selection design.<xref rid="cas13550-bib-0028" ref-type="ref">28</xref> In April 2012, during the accrual period, central monitoring showed a 1&#x02010;year PFS of 21.0% (95% CI, 5.9%&#x02010;42.4%) in a total of 20 patients. The patient accrual did not proceed as planned partly because bortezomib was approved for patients with newly diagnosed MM in 2011 in Japan. Due to a lower 1&#x02010;year PFS than expected and the poor accrual, the sample size was revised to 44 patients to select the better arm in a 1&#x02010;year PFS of 35% to the worst arm in that of 25% with a correct selection probability of 75% by a protocol amendment in October 2012.</p><p>The OS and PFS curves were calculated using the Kaplan&#x02010;Meier method,<xref rid="cas13550-bib-0029" ref-type="ref">29</xref> and HRs and their CIs were estimated using the Cox proportional hazard model. Prespecified subgroup analyses were carried out according to the cytogenetically defined risk groups. The commonly detectable chromosomal translocations involving immunoglobulin heavy chain genes included t(11;14)(q13;q32), t(4;14)(p16;q32), and t(14;16)(q32;q23). Patients with t(4;14)&#x02010; and t(14;16)&#x02010;positive MM cells, which overexpress <italic>FGFR3</italic> and <italic>c&#x02010;MAF</italic> mRNA, respectively, were categorized to the high&#x02010;risk group.<xref rid="cas13550-bib-0030" ref-type="ref">30</xref>, <xref rid="cas13550-bib-0031" ref-type="ref">31</xref> In contrast, those expressing neither <italic>FGFR3</italic> nor <italic>c&#x02010;MAF</italic> mRNA were categorized as the standard&#x02010;risk group. The expression levels of <italic>CCND1</italic>,<italic> FGFR3</italic>, and <italic>c&#x02010;MAF</italic> mRNAs as well as <italic>ACTB</italic> (internal control) were analyzed by global real&#x02010;time quantitative RT&#x02010;PCR as described previously.<xref rid="cas13550-bib-0032" ref-type="ref">32</xref>, <xref rid="cas13550-bib-0033" ref-type="ref">33</xref>
</p><p>Two&#x02010;sided <italic>P</italic>&#x02010;values were calculated for all tests. All statistical analyses in the primary analysis in June 2016 were undertaken using SAS software, release 9.2 (SAS Institute, Cary, NC, USA).</p></sec></sec><sec id="cas13550-sec-0010"><label>3</label><title>RESULTS</title><sec id="cas13550-sec-0011"><label>3.1</label><title>Patients</title><p>Between February 2010 and October 2014, 44 patients were randomized and assigned to receive the BD and TD regimens (n&#x000a0;=&#x000a0;22 each). The characteristics of the 44 patients are shown in Table&#x000a0;<xref rid="cas13550-tbl-0001" ref-type="table-wrap">1</xref>. The median ages of the patients in the BD and TD arms were 65 (range, 44&#x02010;75) years and 66.5 (range, 57&#x02010;76) years, respectively. Twelve patients in each arm (54.5%) had previously received upfront high&#x02010;dose melphalan with the aid of an ASCT. Seventeen patients in each arm (77.3%) had received one prior regimen, and 22.7% of the patients (5 patients in each arm) had received two or more prior regimens. Three patients randomized to the TD arm had received prior lenalidomide treatment. The best response to prior Ld therapy in these patients was partial response in one and SD in two, whereas all of them became refractory to lenalidomide when enrolled in this study. The number of patients showing high&#x02010;risk features represented by the ectopic expression of <italic>FGFR3</italic> or <italic>c&#x02010;MAF</italic> mRNAs were 6 and 8 in the BD and TD arms, respectively. Abnormal G&#x02010;banded karyotype, as another poor prognostic factor, was observed in 7 patients each in the BD and TD arms. Other patient characteristics appeared to be well balanced between the 2 arms.</p><table-wrap id="cas13550-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of Japanese patients with relapsed or refractory multiple myeloma randomized to bortezomib&#x000a0;+&#x000a0;dexamethasone (BD) or thalidomide&#x000a0;+&#x000a0;dexamethasone (TD) treatment arms (n&#x000a0;=&#x000a0;44)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">BD (n&#x000a0;=&#x000a0;22)</th><th align="center" valign="top" rowspan="1" colspan="1">TD (n&#x000a0;=&#x000a0;22)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years; median (range)</td><td align="center" rowspan="1" colspan="1">65 (44&#x02010;77)</td><td align="center" rowspan="1" colspan="1">66.5 (57&#x02010;76)</td></tr><tr><td align="left" colspan="3" rowspan="1">Sex</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">13</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">9</td></tr><tr><td align="left" colspan="3" rowspan="1">Performance status (ECOG)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">9</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">12</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">3 due to bone lesions</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="3" rowspan="1">ISS disease stage at initial diagnosis</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">I</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">II</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">11</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">III</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Not reported</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="3" rowspan="1">ISS disease stage at randomization</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">I</td><td align="char" char="." rowspan="1" colspan="1">16</td><td align="char" char="." rowspan="1" colspan="1">18</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">II</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">III</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" colspan="3" rowspan="1">Disease status</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Primary refractory</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Relapsed or relapsed and refractory</td><td align="char" char="." rowspan="1" colspan="1">22</td><td align="char" char="." rowspan="1" colspan="1">21</td></tr><tr><td align="left" rowspan="1" colspan="1">Time from diagnosis to randomization, months; median (range)</td><td align="char" char="." rowspan="1" colspan="1">27.6 (9.3&#x02010;117.4)</td><td align="char" char="." rowspan="1" colspan="1">27.8 (3.6&#x02010;75.5)</td></tr><tr><td align="left" colspan="3" rowspan="1">M&#x02010;protein class</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">IgG</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">9</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">IgA</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Light chains only</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">6</td></tr><tr><td align="left" colspan="3" rowspan="1">G&#x02010;banded karyotype</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Normal</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">15</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Abnormal</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">NA</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="3" rowspan="1">Chromosomal translocation&#x02010;associated gene expression</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">
<italic>CCND1</italic>
</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">
<italic>FGFR3</italic>
</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">
<italic>c&#x02010;MAF</italic>
</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Not expressed</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">NA*</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" colspan="3" rowspan="1">Number of prior regimens</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">17</td><td align="char" char="." rowspan="1" colspan="1">17</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="3" rowspan="1">Prior therapies</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Upfront ASCT</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">12</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">MP&#x02010;like regimen</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">8</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">VAD&#x02010;like regimen</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">11</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lenalidomide</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr></tbody></table><table-wrap-foot><fn id="cas13550-note-0002"><p>ASCT, autologous stem cell transplantation; ISS, International Staging System; MP, melphalan&#x000a0;+&#x000a0;prednisolone; NA, not assessed; VAD, vincristine, doxorubicin&#x000a0;+&#x000a0;dexamethasone.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="cas13550-sec-0012"><label>3.2</label><title>Feasibility</title><p>The study profile at the data cut&#x02010;off date of December 11, 2015 is shown in Figure&#x000a0;<xref rid="cas13550-fig-0001" ref-type="fig">1</xref>. The median follow&#x02010;up period was 34.3&#x000a0;months. Among the 22 patients allocated in the BD arm, 9 (40.9%) had completed 8 cycles of the induction phase and 4 (18.2%) had completed at least 6 cycles of the maintenance phase. At the cut&#x02010;off date, only 1 patient remained on the protocol treatment. Eight of the 22 patients in the TD arm (36.4%) completed 8 cycles of the induction phase, and 7 (31.8%) patients completed at least 6 cycles of the maintenance phase. At the cut&#x02010;off date, just 1 patient remained on treatment. The median cycles of the induction phase were 6 (range, 2&#x02010;8) and 5.5 (range, 1&#x02010;8) in the BD and TD arms, respectively. Among those who received maintenance phase, the median cycles were 6 (range, 2&#x02010;25) and 10 (range, 2&#x02010;28) in the BD and TD arms, respectively. As shown in Figure&#x000a0;<xref rid="cas13550-fig-0001" ref-type="fig">1</xref>, discontinuation due to disease progression was more frequent in the BD arm compared to the TD arm during the maintenance phase (ie, 5 of 9 vs 1 of 8).</p><fig fig-type="Figure" xml:lang="en" id="cas13550-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow diagram of randomized patients with relapsed or refractory multiple myeloma who were enrolled in the <styled-content style="fixed-case">JCOG</styled-content>0904 study comparing bortezomib plus dexamethasone (<styled-content style="fixed-case">BD</styled-content>) vs thalidomide plus dexamethasone (<styled-content style="fixed-case">TD</styled-content>)</p></caption><graphic id="nlm-graphic-3" xlink:href="CAS-109-1552-g001"/></fig></sec><sec id="cas13550-sec-0013"><label>3.3</label><title>Efficacy</title><sec id="cas13550-sec-0014"><label>3.3.1</label><title>Progression&#x02010;free survival</title><p>Median PFS in the 44 patients was 7.0&#x000a0;months (95% CI, 3.0&#x02010;12.5) (Figure&#x000a0;<xref rid="cas13550-sup-0001" ref-type="supplementary-material">S1</xref>A). The 1&#x02010; and 3&#x02010;year PFS were 38.6% (95% CI, 24.5%&#x02010;52.6%) and 12.5% (95% CI, 4.4%&#x02010;25.2%), respectively. Furthermore, the 1&#x02010;year PFS in the BD and TD arms were 45.5% (95% CI, 24.4%&#x02010;64.3%) and 31.8% (95% CI, 14.2%&#x02010;51.1%), respectively; the median PFS was 10.9&#x000a0;months (95% CI, 5.2&#x02010;18.7&#x000a0;months) and 3.2&#x000a0;months (95% CI, 2.1&#x02010;12.5&#x000a0;months), respectively. The HR in the TD arm when compared to the BD arm was 1.76 (95% CI, 0.92&#x02010;3.37; Figure&#x000a0;<xref rid="cas13550-fig-0002" ref-type="fig">2</xref>A). The BD arm tended to show better PFS than the TD arm in spite of the age (&#x02264;64 or &#x0003e;64&#x000a0;years), gender, performance status (0 or &#x02265;1), presence or absence of upfront ASCT, and number of prior therapies (1 or &#x02265;2), but not in the patients with International Staging System stage &#x02265;II during registration. The HR of the BD arm to the TD arm in PFS with multivariable analysis was almost the same as that seen in the univariable primary analysis. Progression&#x02010;free survival was compared between the high&#x02010;risk and standard&#x02010;risk groups in the BD and TD arms, wherein PFS was found to be similar between both groups in both the treatment arms, although the number of patients in each group was too small (Figure&#x000a0;<xref rid="cas13550-sup-0002" ref-type="supplementary-material">S2</xref>). In the TD arm, the numbers of patients who were on thalidomide at 200&#x000a0;mg/d and &#x02264;100&#x000a0;mg/d were 14 and 8, and their 1&#x02010;year PFS was 28.6% (95% CI, 8.8%&#x02010;52.4%) and 37.5% (95% CI, 8.7%&#x02010;67.4%), respectively.</p><fig fig-type="Figure" xml:lang="en" id="cas13550-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Progression&#x02010;free survival (A) and overall survival (B) of patients with relapsed or refractory multiple myeloma who were randomized to bortezomib plus dexamethasone (<styled-content style="fixed-case">BD</styled-content>) or thalidomide plus dexamethasone (<styled-content style="fixed-case">TD</styled-content>) treatment arms from the time of study enrollment</p></caption><graphic id="nlm-graphic-5" xlink:href="CAS-109-1552-g002"/></fig></sec><sec id="cas13550-sec-0015"><label>3.3.2</label><title>Response</title><p>The best ORR was 77.3% (17/22; 95% CI, 54.6%&#x02010;92.2%) and 40.9% (9/22, 95% CI, 20.7%&#x02010;63.7%) in the BD and TD arms, respectively (Table&#x000a0;<xref rid="cas13550-tbl-0002" ref-type="table-wrap">2</xref>). A higher ORR was consistently observed in the BD arm when compared with the TD arm in the standard&#x02010;risk group (83.3% [10/12] vs 36.4% [4/11]) and the high&#x02010;risk group (83.3% [5/6] vs 50.0% [4/8]). In the TD arm, the ORR of the patients who were on thalidomide 200&#x000a0;mg/d and &#x02264;100&#x000a0;mg/d was 28.6% (95% CI, 8.8%&#x02010;52.4%) and 37.5% (95% CI, 8.7%&#x02010;67.4%), respectively.</p><table-wrap id="cas13550-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Best overall response in Japanese patients with relapsed or refractory multiple myeloma randomized to bortezomib&#x000a0;+&#x000a0;dexamethasone (BD) or thalidomide&#x000a0;+&#x000a0;dexamethasone (TD) treatment arms (n&#x000a0;=&#x000a0;44)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Best response</th><th align="left" valign="top" rowspan="1" colspan="1">BD (n<italic>&#x000a0;</italic>=&#x000a0;22)</th><th align="left" valign="top" rowspan="1" colspan="1">TD (n<italic>&#x000a0;</italic>=&#x000a0;22)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Overall response rate<xref ref-type="fn" rid="cas13550-note-0004">a</xref>
</td><td align="left" rowspan="1" colspan="1">77.3 (95% CI, 54.6&#x02010;92.2)</td><td align="left" rowspan="1" colspan="1">40.9 (95% CI, 20.7&#x02010;63.7)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" colspan="2" rowspan="1">
<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>.0305</td></tr><tr><td align="left" colspan="3" rowspan="1">Best response</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stringent complete response</td><td align="left" rowspan="1" colspan="1">1 (4.5)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Complete response</td><td align="left" rowspan="1" colspan="1">1 (4.5)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Very good partial response</td><td align="left" rowspan="1" colspan="1">2 (9.1)</td><td align="left" rowspan="1" colspan="1">3 (13.6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Partial response</td><td align="left" rowspan="1" colspan="1">13 (59.1)</td><td align="left" rowspan="1" colspan="1">6 (27.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stable disease</td><td align="left" rowspan="1" colspan="1">4 (18.2)</td><td align="left" rowspan="1" colspan="1">7 (31.8)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Progressive disease</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">5 (22.7)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Not evaluable</td><td align="left" rowspan="1" colspan="1">1 (4.5)</td><td align="left" rowspan="1" colspan="1">1 (4.5)</td></tr></tbody></table><table-wrap-foot><fn id="cas13550-note-0003"><p>CI, confidence interval.</p></fn><fn id="cas13550-note-0004"><label>a</label><p>Partial response or better.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="cas13550-sec-0016"><label>3.3.3</label><title>Overall survival</title><p>Median OS in the 44 patients was 46.0&#x000a0;months (95% CI, 30.0&#x02010;not reached) (Figure&#x000a0;<xref rid="cas13550-sup-0001" ref-type="supplementary-material">S1</xref>B). The 1&#x02010;, 3&#x02010;, and 5&#x02010;year OS were 86.4% (95% CI, 72.1%&#x02010;93.6%), 59.7% (95% CI, 42.6%&#x02010;73.2%), and 46.0% (95% CI, 27.5%&#x02010;62.8%), respectively. The 1&#x02010;, 3&#x02010;, and 5&#x02010;year OS in the BD arm were 90.9% (95% CI, 68.3%&#x02010;97.6%), 70.0% (95% CI, 44.9%&#x02010;85.4%), and 51.1% (95% CI, 22.8%&#x02010;73.7%) respectively; those in the TD arm were 81.8% (95% CI, 58.5%&#x02010;92.8%), 48.8% (95% CI, 25.1%&#x02010;69.0%), and 40.7% (95% CI, 17.6%&#x02010;62.8%), respectively (Figure&#x000a0;<xref rid="cas13550-fig-0002" ref-type="fig">2</xref>B). The HR in the TD arm was 1.60 (95% CI, 0.64&#x02010;3.99) when compared with the BD arm.</p></sec></sec><sec id="cas13550-sec-0017"><label>3.4</label><title>Safety profile</title><p>Toxicities during the induction phases in each arm are shown in Table&#x000a0;<xref rid="cas13550-tbl-0003" ref-type="table-wrap">3</xref>. As with hematologic toxicity, the most common grade 3 or higher AEs in the BD and TD arms were leukocytopenia (18.2% vs 13.6%), neutropenia (13.6% vs 13.6%), and thrombocytopenia (54.5% vs 0.0%). Thrombocytopenia &#x02265;grade 3 was more frequent in the BD arm. Non&#x02010;hematologic toxicities during the induction phases are shown in Table&#x000a0;<xref rid="cas13550-tbl-0003" ref-type="table-wrap">3</xref>. The non&#x02010;hematologic AEs of &#x02265;grade 3 that were observed in &#x02265;2 patients in the BD arm included constipation (13.6%), sensory PN (22.7%), motor PN (9.1%), increased AST/ALT (13.6%), hyponatremia (9.1%), and hypokalemia (9.1%), and those in the TD arm were fatigue (13.6%), sensory PN (9.1%), and hyperglycemia (13.6%). The development of herpes zoster was noted in 1 patient assigned to the TD arm (4.5%), whereas none of the patients in the BD arm developed the condition. Furthermore, venous thromboembolism was reported in 1 patient (4.5%) in the TD arm. Of the infections &#x02265;grade 2 that delayed the initiation of subsequent cycles, pneumonia was reported in 3 (13.6%) patients each in the BD and TD arms. Grade 3 or higher pneumonia was seen in 1 and 3 patients in the BD and TD arms, respectively; one of the cases in the TD arm resulted in a treatment&#x02010;related death. Grade 2 pharyngitis was observed in 4 patients in the BD arm and 1 patient in the TD arm. The other grade 2 infections included bronchitis in 1 patient (TD arm), bacterial meningitis in 1 patient (BD arm), and cytomegalovirus infection in 1 patient (TD arm). In addition to these events, reactivation of HBV occurred without hepatitis development in a patient with resolved HBV in the BD arm. Entecavir was provided to the patient pre&#x02010;emptively, following which HBV&#x02010;DNA was promptly undetectable. In the TD arm, the incidence of &#x02265;grade 2 AEs during the induction phase was similar in patients treated with thalidomide 200&#x000a0;mg/d or &#x02264;100&#x000a0;mg/d (64.3% vs 62.5%).</p><table-wrap id="cas13550-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Adverse events of Japanese patients with relapsed or refractory multiple myeloma during the induction phase of treatment with bortezomib&#x000a0;+&#x000a0;dexamethasone (BD) or thalidomide&#x000a0;+&#x000a0;dexamethasone (TD)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" valign="top" colspan="1">Event, n (%)</th><th align="center" colspan="6" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">BD (n&#x000a0;=&#x000a0;22)</th><th align="center" colspan="6" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">TD (n&#x000a0;=&#x000a0;22)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" colspan="6" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Grade</th><th align="center" colspan="6" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Grade</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">1</th><th align="center" valign="top" rowspan="1" colspan="1">2</th><th align="left" valign="top" rowspan="1" colspan="1">3</th><th align="left" valign="top" rowspan="1" colspan="1">4</th><th align="center" valign="top" rowspan="1" colspan="1">Total %</th><th align="center" valign="top" rowspan="1" colspan="1">G3/4%</th><th align="center" valign="top" rowspan="1" colspan="1">1</th><th align="center" valign="top" rowspan="1" colspan="1">2</th><th align="left" valign="top" rowspan="1" colspan="1">3</th><th align="left" valign="top" rowspan="1" colspan="1">4</th><th align="center" valign="top" rowspan="1" colspan="1">Total %</th><th align="center" valign="top" rowspan="1" colspan="1">G3/4%</th></tr></thead><tbody><tr><td align="left" colspan="13" rowspan="1">Hematologic toxicity</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Leukopenia</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">72.7</td><td align="char" char="." rowspan="1" colspan="1">18.2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">50.0</td><td align="char" char="." rowspan="1" colspan="1">13.6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Neutropenia</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">86.4</td><td align="char" char="." rowspan="1" colspan="1">13.6</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">81.8</td><td align="char" char="." rowspan="1" colspan="1">13.6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Anemia</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">95.5</td><td align="char" char="." rowspan="1" colspan="1">9.1</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">95.5</td><td align="char" char="." rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Thrombocytopenia</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">100.0</td><td align="char" char="." rowspan="1" colspan="1">54.5</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">77.3</td><td align="char" char="." rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" colspan="13" rowspan="1">Non&#x02010;hematologic toxicity</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypoalbuminemia</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." rowspan="1" colspan="1">95.5</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." rowspan="1" colspan="1">100.0</td><td align="char" char="." rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ALP increased</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">40.9</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">36.4</td><td align="char" char="." rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">AST increased</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">59.1</td><td align="char" char="." rowspan="1" colspan="1">13.6</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">40.9</td><td align="char" char="." rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ALT increased</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">72.7</td><td align="char" char="." rowspan="1" colspan="1">13.6</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">63.6</td><td align="char" char="." rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cr increased</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">45.5</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">59.1</td><td align="char" char="." rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypernatremia</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">13.6</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">9.1</td><td align="char" char="." rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hyponatremia</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">68.2</td><td align="char" char="." rowspan="1" colspan="1">9.1</td><td align="char" char="." rowspan="1" colspan="1">21</td><td align="char" char="." rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">95.5</td><td align="char" char="." rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hyperkalemia</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">40.9</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">63.6</td><td align="char" char="." rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypokalemia</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">40.9</td><td align="char" char="." rowspan="1" colspan="1">9.1</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">27.3</td><td align="char" char="." rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypercalcemia</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">9.1</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">36.4</td><td align="char" char="." rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypocalcemia</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">59.1</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">59.1</td><td align="char" char="." rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hyperglycemia</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">77.3</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">95.5</td><td align="char" char="." rowspan="1" colspan="1">13.6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fever</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">27.3</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">18.2</td><td align="char" char="." rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fatigue</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">36.4</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">45.5</td><td align="char" char="." rowspan="1" colspan="1">13.6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Rash</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">18.2</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">18.2</td><td align="char" char="." rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nausea</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">31.8</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">13.6</td><td align="char" char="." rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Anorexia</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">36.4</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">9.1</td><td align="char" char="." rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Vomiting</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">22.7</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diarrhea</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">31.8</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Constipation</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">68.2</td><td align="char" char="." rowspan="1" colspan="1">13.6</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">59.1</td><td align="char" char="." rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Paralytic ileus</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">9.1</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mucositis</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">9.1</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Herpes zoster</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Somnolence</td><td align="char" char="." rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">13.6</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">9.1</td><td align="char" char="." rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Peripheral neuropathy, motor</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">13.6</td><td align="char" char="." rowspan="1" colspan="1">9.1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">9.1</td><td align="char" char="." rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Peripheral neuropathy, sensory</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">86.4</td><td align="char" char="." rowspan="1" colspan="1">22.7</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">54.5</td><td align="char" char="." rowspan="1" colspan="1">9.1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypoxia</td><td align="char" char="." rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pneumonitis</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Thrombosis</td><td align="char" char="." rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">0.0</td></tr></tbody></table><table-wrap-foot><fn id="cas13550-note-0005"><p>Adverse events categorized according to according to the NCI's Common Terminology Criteria for Adverse Events version 3.0. &#x02010;, not defined. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, creatinine.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>During the maintenance phase, grade 3 neutropenia was observed in 3 patients (33.3%) and grade 3 thrombocytopenia in 1 patient (11.1%) in the BD arm; however, none of the patients in the TD arm presented with either of these conditions. Furthermore, no grade 3 or higher non&#x02010;hematologic AEs were observed in either treatment arm (Table&#x000a0;<xref rid="cas13550-sup-0004" ref-type="supplementary-material">S1</xref>).</p><p>Death during protocol treatment or within 30&#x000a0;days of the last treatment occurred in 2 patients. One patient died from respiratory failure due to rapid extramedullary disease progression in the right thorax 10&#x000a0;days after completion of cycle 3 of the induction phase in the BD arm. Another patient died from pneumonia during cycle 3 of the induction phase in the TD arm, and was therefore considered as a treatment&#x02010;related death.</p><p>Only 1 patient from the TD arm developed secondary malignancy (colon cancer). It was surgically resected, and the patient has remained free of cancer.</p></sec></sec><sec id="cas13550-sec-0018"><label>4</label><title>DISCUSSION</title><p>In this study, we compared the 1&#x02010;year PFS in order to identify a promising doublet regimen for patients with bortezomib&#x02010; and thalidomide&#x02010;na&#x000ef;ve RRMM from the BD and TD regimens. The 1&#x02010;year PFS in patients belonging to the BD arm was superior to that in the TD arm. During the planning and initiation of this randomized phase II study, lenalidomide, another promising agent, was not available in Japan.<xref rid="cas13550-bib-0012" ref-type="ref">12</xref>, <xref rid="cas13550-bib-0013" ref-type="ref">13</xref>, <xref rid="cas13550-bib-0014" ref-type="ref">14</xref> Accordingly, the more successful regimen in this study was supposed to be compared with LD or the Ld regimen in a subsequent phase III trial. During the period of patient enrollment, lenalidomide was approved for patients with RRMM in June 2010. In addition, bortezomib was approved for patients with newly diagnosed MM in 2011,<xref rid="cas13550-bib-0034" ref-type="ref">34</xref>, <xref rid="cas13550-bib-0035" ref-type="ref">35</xref> which might have resulted in a remarkable drop in patient accrual, and was one of the reasons for the major protocol amendment.</p><p>In the current study, the 1&#x02010;year PFS was superior in the BD arm when compared with the TD arm, despite the higher incidence of &#x02265;grade 3 thrombocytopenia and PN in the BD regimen. Patient characteristics of both arms were well balanced; except for the assignment of all 3 patients who had received a prior lenalidomide regimen to the TD arm. However, two of the 3 patients achieved SD and the PFS of these 3 patients were 6.93, 4.17, and 0.95&#x000a0;months, which were comparable to the median PFS of 3.2&#x000a0;months in all patients assigned to the TD arm. In fact, thalidomide&#x02010;containing therapies consisting mainly of the TD regimen have shown minimal response or better in 40% of the patients who showed resistance to prior LD and the median PFS of 5.5&#x000a0;months was documented.<xref rid="cas13550-bib-0036" ref-type="ref">36</xref> This observation suggested that response to lenalidomide might not be predictive of thalidomide response and that different mechanisms of action might exist between thalidomide and lenalidomide.</p><p>In line with the PFS data, the best ORR in the BD arm (77.3%) was higher than that in the TD arm (40.9%) in this study. Moreover, CR or stringent complete response in 2 of 22 patients (9.1%) was obtained in the BD arm but not in the TD arm. Consistently, higher ORR was observed in patients in both standard&#x02010;risk and high&#x02010;risk groups in the BD when compared to the TD arm. Therefore, the BD regimen appears to be more effective for both standard&#x02010; and high&#x02010;risk MM, as reported previously.<xref rid="cas13550-bib-0031" ref-type="ref">31</xref>, <xref rid="cas13550-bib-0037" ref-type="ref">37</xref> However, the number of patients analyzed for this assay was too small, warranting the need for further large&#x02010;scale studies to confirm these findings.</p><p>In the current study, the longer PFS in the BD arm might be associated with a longer OS when compared to that of the TD arm. The patients with disease progression were not offered a crossover treatment to alternative regimens in this study. Subsequent salvage therapies after discontinuation of the protocol treatment were given in 17 and 19 patients in the BD and TD arms, respectively (Table&#x000a0;<xref rid="cas13550-sup-0005" ref-type="supplementary-material">S2</xref>). In the BD arm, lenalidomide&#x02010; or thalidomide&#x02010;containing regimens were chosen most frequently (13 patients; 61.9%). In contrast, in the TD arm, bortezomib&#x02010;containing regimens were chosen most often (15 patients; 71.4%). The longer OS in the BD arm when compared with the TD arm in this study may indicate that the use of the BD regimen followed by an LD or TD regimen results in a higher OS when compared to the use of the TD regimen followed by the BD regimen in patients with RRMM. Notably, the median OS of the patients after progression was quite long, probably because they had the opportunity to access novel drugs approved after initiation of this study.<xref rid="cas13550-bib-0038" ref-type="ref">38</xref>, <xref rid="cas13550-bib-0039" ref-type="ref">39</xref>
</p><p>In terms of the efficacy end&#x02010;points, the results of the present study were not in accordance with that of a randomized phase III study reported by the NMSG,<xref rid="cas13550-bib-0040" ref-type="ref">40</xref> which compared TD with BD for RRMM. In an NMSG trial, the median PFS was similar between the BD and TD groups at 7.2 and 9.0&#x000a0;months, respectively. The NMSG study was different from the present study in the following aspects: melphalan&#x02010;refractory patients were enrolled, thalidomide was escalated to a maximum of 200&#x000a0;mg daily, and treatment was paused when the patient achieved best response and reinstituted in case of progression. The median age of the patients (71&#x000a0;years in both treatment arms) was also higher in the NMSG trial. This could be a reason why the NMSG study did not show better PFS in the BD arm than the TD arm, as the PFS benefit by the BD regimen seemed smaller in the elderly population. In fact, subgroup analyses of patients aged &#x0003c;65&#x000a0;years (n&#x000a0;=&#x000a0;18) and &#x02265;65&#x000a0;years (n&#x000a0;=&#x000a0;26) were undertaken in our study. As shown in Figure&#x000a0;<xref rid="cas13550-sup-0003" ref-type="supplementary-material">S3</xref>, the 1&#x02010;year PFS was 60.0% (95% CI, 25.3%&#x02010;82.7%) in the BD arm and 25.0% (95% CI, 3.7%&#x02010;55.8%) in the TD arm among patients aged &#x0003c;65&#x000a0;years (Figure&#x000a0;<xref rid="cas13550-sup-0003" ref-type="supplementary-material">S3</xref>). In contrast, the 1&#x02010;year PFS was 33.3% (95% CI, 10.3%&#x02010;58.8%) in the BD arm and 35.7% (95% CI, 13.0%&#x02010;59.4%) in the TD arm in patients aged &#x02265;65&#x000a0;years. For patients &#x02265;71&#x000a0;years, the 1&#x02010;year PFS was 33.3% (95% CI, 7.8%&#x02010;62.3%) in the BD arm (n&#x000a0;=&#x000a0;9) and 50.0% (95% CI, 15.2%&#x02010;77.5%) in the TD arm (n&#x000a0;=&#x000a0;8). Thus, the PFS was not very different between the two arms in the elderly cohort, suggesting that elderly patients might not benefit from BD compared to TD therapy.</p><p>No remarkable differences in serious toxicities were noted. Eight (36%) and 5 (23%) patients in the BD and TD arms, respectively, discontinued induction treatment due to either AEs or patient refusal related to AEs. Grade 3 sensory PN was observed in 22.7% of the patients in the BD arm, and it was the most frequent reason for AE&#x02010;related discontinuation (4/8; 50%). Bortezomib was given i.v. in approximately two&#x02010;thirds of the patients assigned to the BD arm. Currently, the incidence of serious PN can be reduced when bortezomib is given s.c. without reducing its efficacy.<xref rid="cas13550-bib-0041" ref-type="ref">41</xref> However, the relatively lower incidence of grade 3 PN in the TD arm might partly be explained by the shorter treatment period when compared with the BD arm. No serious venous thromboembolism was experienced in the present study with recommendation of the prophylactic use of low&#x02010;dose aspirin or warfarin for the patients enrolled in the TD arm.<xref rid="cas13550-bib-0024" ref-type="ref">24</xref>
</p><p>Recently, triplet regimens for patients with RRMM have shown higher efficacy, including higher CR (11.0%&#x02010;31.8%) rate and longer PFS (median PFS, 12.0&#x02010;26.3&#x000a0;months) when compared to classical doublet regimens.<xref rid="cas13550-bib-0015" ref-type="ref">15</xref>, <xref rid="cas13550-bib-0018" ref-type="ref">18</xref>, <xref rid="cas13550-bib-0019" ref-type="ref">19</xref>, <xref rid="cas13550-bib-0020" ref-type="ref">20</xref> More recently, anti&#x02010;CD38 mAb, daratumumab, in combination with BD or Ld have shown high CR rates (19.2% and 43.1%, respectively) with longer PFS (1&#x02010;year PFS, 60.7% and 83.2%, respectively).<xref rid="cas13550-bib-0016" ref-type="ref">16</xref>, <xref rid="cas13550-bib-0017" ref-type="ref">17</xref> Although the optimal strategy for RRMM has not been established, a sequential approach using classical doublet regimens is convenient as they are given orally or s.c. in an outpatient setting. The adverse events are familiar and easy to manage, as they do not overlap each other as seen in the case of triplet regimens. Accordingly, the doublet regimens remain an option for use, especially in elderly patients or in those with daily jobs.</p><p>In conclusion, based on the better 1&#x02010;year PFS in the BD than in the TD treatment arm, BD therapy was prioritized over TD therapy for use in novel&#x02010;agent&#x02010;na&#x000ef;ve patients with RRMM in further investigations.</p></sec><sec id="cas13550-sec-0020"><title>CONFLICT OF INTEREST</title><p>S.I., J.K., K.T., and K.T. have received honoraria from Janssen and Takeda. D.M., K.M. and H.N. have received honoraria from Takeda. S.I., D.M., J.K., H.N., and K.T. have received research funding from Janssen and Takeda. K.Y. and Y.M. have received research funding from Takeda.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="cas13550-sup-0001"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-109-1552-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas13550-sup-0002"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-109-1552-s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas13550-sup-0003"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-109-1552-s003.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas13550-sup-0004"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-109-1552-s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas13550-sup-0005"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-109-1552-s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas13550-sup-0006"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-109-1552-s006.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="cas13550-sec-0019"><title>ACKNOWLEDGMENTS</title><p>We extend our appreciation to all of the patients, families, and caregivers who participated in this multicenter trial. We are also grateful to the members of the JCOG Data Center, especially Ms. Y. Watanabe, Mr. T. Shibata, and Dr. H. Fukuda, and the JCOG committees for their critical advice in carrying out the study. This study was supported in part by the National Cancer Center Research and Development Fund (26&#x02010;A&#x02010;4 and 29&#x02010;A&#x02010;3) and by Grants&#x02010;in&#x02010;Aid from the Ministry of Health, Labor and Welfare of Japan (201119011C, to S.I.).</p></ack><ref-list content-type="cited-references" id="cas13550-bibl-0001"><title>REFERENCES</title><ref id="cas13550-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cas13550-cit-0001">
<string-name>
<surname>Kumar</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Dispenzieri</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lacy</surname>
<given-names>MQ</given-names>
</string-name>, et&#x000a0;al. <article-title>Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients</article-title>. <source xml:lang="en">Leukemia</source>. <year>2014</year>;<volume>28</volume>:<fpage>1122</fpage>&#x02010;<lpage>1128</lpage>.<pub-id pub-id-type="pmid">24157580</pub-id></mixed-citation></ref><ref id="cas13550-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cas13550-cit-0002">
<string-name>
<surname>Ozaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Handa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Saitoh</surname>
<given-names>T</given-names>
</string-name>, et&#x000a0;al. <article-title>Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma</article-title>. <source xml:lang="en">Blood Cancer J</source>. <year>2015</year>;<volume>18</volume>:<fpage>e349</fpage>.</mixed-citation></ref><ref id="cas13550-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cas13550-cit-0003">
<string-name>
<surname>Ogawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tobinai</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ogura</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Phase I/II and pharmacokinetic/pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma</article-title>. <source xml:lang="en">Cancer Sci</source>. <year>2007</year>;<volume>99</volume>:<fpage>140</fpage>&#x02010;<lpage>144</lpage>.<pub-id pub-id-type="pmid">17970782</pub-id></mixed-citation></ref><ref id="cas13550-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cas13550-cit-0004">
<string-name>
<surname>Richardson</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Sonneveld</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Schuster</surname>
<given-names>MW</given-names>
</string-name>, et&#x000a0;al. <article-title>Bortezomib or high&#x02010;dose dexamethasone for relapsed multiple myeloma</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2005</year>;<volume>352</volume>:<fpage>2487</fpage>&#x02010;<lpage>2498</lpage>.<pub-id pub-id-type="pmid">15958804</pub-id></mixed-citation></ref><ref id="cas13550-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cas13550-cit-0005">
<string-name>
<surname>Jagannath</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Richardson</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Barlogie</surname>
<given-names>B</given-names>
</string-name>, et&#x000a0;al. <article-title>Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone</article-title>. <source xml:lang="en">Haematologica</source>. <year>2006</year>;<volume>91</volume>:<fpage>929</fpage>&#x02010;<lpage>934</lpage>.<pub-id pub-id-type="pmid">16818280</pub-id></mixed-citation></ref><ref id="cas13550-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cas13550-cit-0006">
<string-name>
<surname>Richardson</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Barlogie</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Berenson</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>A phase 2 study of bortezomib in relapsed, refractory myeloma</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2003</year>;<volume>348</volume>:<fpage>2609</fpage>&#x02010;<lpage>2617</lpage>.<pub-id pub-id-type="pmid">12826635</pub-id></mixed-citation></ref><ref id="cas13550-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cas13550-cit-0007">
<string-name>
<surname>Murakami</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Shimizu</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sawamura</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma</article-title>. <source xml:lang="en">Int J Hematol</source>. <year>2009</year>;<volume>89</volume>:<fpage>636</fpage>&#x02010;<lpage>641</lpage>.<pub-id pub-id-type="pmid">19399582</pub-id></mixed-citation></ref><ref id="cas13550-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cas13550-cit-0008">
<string-name>
<surname>Glasmacher</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hahn</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hoffmann</surname>
<given-names>F</given-names>
</string-name>, et&#x000a0;al. <article-title>A systematic review of phase II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma</article-title>. <source xml:lang="en">Br J Haematol</source>. <year>2006</year>;<volume>132</volume>:<fpage>584</fpage>&#x02010;<lpage>593</lpage>.<pub-id pub-id-type="pmid">16445831</pub-id></mixed-citation></ref><ref id="cas13550-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cas13550-cit-0009">
<string-name>
<surname>Von Lilienfeld&#x02010;Toal</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hahn&#x02010;Ast</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Furkert</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma</article-title>. <source xml:lang="en">Eur J Haematol</source>. <year>2008</year>;<volume>81</volume>:<fpage>247</fpage>&#x02010;<lpage>252</lpage>.<pub-id pub-id-type="pmid">18637031</pub-id></mixed-citation></ref><ref id="cas13550-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cas13550-cit-0010">
<string-name>
<surname>Murakami</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Handa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Abe</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Low&#x02010;dose thalidomide plus dexamethasone therapy in patients with refractory multiple myeloma</article-title>. <source xml:lang="en">Eur J Hematol</source>. <year>2007</year>;<volume>74</volume>:<fpage>234</fpage>&#x02010;<lpage>239</lpage>.</mixed-citation></ref><ref id="cas13550-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cas13550-cit-0011">
<string-name>
<surname>Ochiai</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yamda</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Uchida</surname>
<given-names>R</given-names>
</string-name>, et&#x000a0;al. <article-title>Combination therapy with thalidomide, incardronate, and dexamethasone for relapsed or refractory multiple myeloma</article-title>. <source xml:lang="en">Int J Hematol</source>. <year>2005</year>;<volume>82</volume>:<fpage>243</fpage>&#x02010;<lpage>247</lpage>.<pub-id pub-id-type="pmid">16207598</pub-id></mixed-citation></ref><ref id="cas13550-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cas13550-cit-0012">
<string-name>
<surname>Weber</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Niesvizky</surname>
<given-names>R</given-names>
</string-name>, et&#x000a0;al. <article-title>Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2007</year>;<volume>357</volume>:<fpage>2133</fpage>&#x02010;<lpage>2142</lpage>.<pub-id pub-id-type="pmid">18032763</pub-id></mixed-citation></ref><ref id="cas13550-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cas13550-cit-0013">
<string-name>
<surname>Dimopoulos</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Spencer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Attal</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2007</year>;<volume>357</volume>:<fpage>2123</fpage>&#x02010;<lpage>2132</lpage>.<pub-id pub-id-type="pmid">18032762</pub-id></mixed-citation></ref><ref id="cas13550-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cas13550-cit-0014">
<string-name>
<surname>Iida</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chou</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Okamoto</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma</article-title>. <source xml:lang="en">Int J Hematol</source>. <year>2010</year>;<volume>92</volume>:<fpage>118</fpage>&#x02010;<lpage>126</lpage>.<pub-id pub-id-type="pmid">20559759</pub-id></mixed-citation></ref><ref id="cas13550-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cas13550-cit-0015">
<string-name>
<surname>Lonial</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dimopoulos</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Palumbo</surname>
<given-names>A</given-names>
</string-name>, et&#x000a0;al. <article-title>Elotuzumab therapy for relapsed or refractory multiple myeloma</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2015</year>;<volume>373</volume>:<fpage>621</fpage>&#x02010;<lpage>631</lpage>.<pub-id pub-id-type="pmid">26035255</pub-id></mixed-citation></ref><ref id="cas13550-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cas13550-cit-0016">
<string-name>
<surname>Palumbo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chanan&#x02010;Khan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Weisel</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>Daratumumab, bortezomib, and dexamethasone for multiple myeloma</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2016</year>;<volume>375</volume>:<fpage>754</fpage>&#x02010;<lpage>766</lpage>.<pub-id pub-id-type="pmid">27557302</pub-id></mixed-citation></ref><ref id="cas13550-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cas13550-cit-0017">
<string-name>
<surname>Dimopoulos</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Oriol</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nahi</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>Daratumumab, lenalidomide, and dexamethasone for multiple myeloma</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2016</year>;<volume>375</volume>:<fpage>1319</fpage>&#x02010;<lpage>1331</lpage>.<pub-id pub-id-type="pmid">27705267</pub-id></mixed-citation></ref><ref id="cas13550-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cas13550-cit-0018">
<string-name>
<surname>San&#x02010;Miguel</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Hungria</surname>
<given-names>VT</given-names>
</string-name>, <string-name>
<surname>Yoon</surname>
<given-names>SS</given-names>
</string-name>, et&#x000a0;al. <article-title>Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicenter, randomized, double&#x02010;blind phase 3 trial</article-title>. <source xml:lang="en">Lancet Oncol</source>. <year>2014</year>;<volume>15</volume>:<fpage>1195</fpage>&#x02010;<lpage>1206</lpage>.<pub-id pub-id-type="pmid">25242045</pub-id></mixed-citation></ref><ref id="cas13550-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cas13550-cit-0019">
<string-name>
<surname>Moreau</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Masszi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Grzasko</surname>
<given-names>N</given-names>
</string-name>, et&#x000a0;al. <article-title>Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2016</year>;<volume>374</volume>:<fpage>1621</fpage>&#x02010;<lpage>1634</lpage>.<pub-id pub-id-type="pmid">27119237</pub-id></mixed-citation></ref><ref id="cas13550-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cas13550-cit-0020">
<string-name>
<surname>Stewart</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Rajkumar</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Dimopoulos</surname>
<given-names>MA</given-names>
</string-name>, et&#x000a0;al. <article-title>Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2014</year>;<volume>372</volume>:<fpage>142</fpage>&#x02010;<lpage>152</lpage>.<pub-id pub-id-type="pmid">25482145</pub-id></mixed-citation></ref><ref id="cas13550-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cas13550-cit-0021">
<string-name>
<surname>Durie</surname>
<given-names>BGM</given-names>
</string-name>, <string-name>
<surname>Hoering</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Abidi</surname>
<given-names>MH</given-names>
</string-name>, et&#x000a0;al. <article-title>Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem&#x02010;cell transplant (SWOG0777): a randomized, open&#x02010;label, phase 3 trial</article-title>. <source xml:lang="en">Lancet</source>. <year>2017</year>;<volume>389</volume>:<fpage>519</fpage>&#x02010;<lpage>527</lpage>.<pub-id pub-id-type="pmid">28017406</pub-id></mixed-citation></ref><ref id="cas13550-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cas13550-cit-0022">
<collab collab-type="authors">The International Myeloma Working Group</collab>
. <article-title>Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group</article-title>. <source xml:lang="en">Br J Haematol</source>. <year>2003</year>;<volume>121</volume>:<fpage>749</fpage>&#x02010;<lpage>757</lpage>.<pub-id pub-id-type="pmid">12780789</pub-id></mixed-citation></ref><ref id="cas13550-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cas13550-cit-0023">
<string-name>
<surname>Chanan&#x02010;Khan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sonneveld</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Schuster</surname>
<given-names>MW</given-names>
</string-name>, et&#x000a0;al. <article-title>Analysis of herpes zoster events among bortezomib&#x02010;treated patients in the phase III APEX study</article-title>. <source xml:lang="en">J Clin Oncol</source>. <year>2008</year>;<volume>26</volume>:<fpage>4784</fpage>&#x02010;<lpage>4790</lpage>.<pub-id pub-id-type="pmid">18711175</pub-id></mixed-citation></ref><ref id="cas13550-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cas13550-cit-0024">
<string-name>
<surname>Palumbo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cavo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bringhen</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open&#x02010;label, randomized trial</article-title>. <source xml:lang="en">J Clin Oncol</source>. <year>2011</year>;<volume>29</volume>:<fpage>986</fpage>&#x02010;<lpage>993</lpage>.<pub-id pub-id-type="pmid">21282540</pub-id></mixed-citation></ref><ref id="cas13550-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cas13550-cit-0025">
<string-name>
<surname>Kusumoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Suzuki</surname>
<given-names>R</given-names>
</string-name>, et&#x000a0;al. <article-title>Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B&#x02010;cell lymphoma: a prospective observational study</article-title>. <source xml:lang="en">Clin Infect Dis</source>. <year>2015</year>;<volume>61</volume>:<fpage>719</fpage>&#x02010;<lpage>729</lpage>.<pub-id pub-id-type="pmid">25935551</pub-id></mixed-citation></ref><ref id="cas13550-bib-0026"><label>26</label><mixed-citation publication-type="book" id="cas13550-cit-0026">
<collab collab-type="authors">National Cancer Institute</collab>
. <source xml:lang="en">Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC)</source>. <publisher-loc>Bethesda, MD, USA</publisher-loc>: <publisher-name>National Cancer Institute</publisher-name>; <year>2007</year>
<ext-link ext-link-type="uri" xlink:href="http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf">http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf</ext-link>
</mixed-citation></ref><ref id="cas13550-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cas13550-cit-0027">
<string-name>
<surname>Durie</surname>
<given-names>BGM</given-names>
</string-name>, <string-name>
<surname>Jacobson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Barlogie</surname>
<given-names>B</given-names>
</string-name>, et&#x000a0;al. <article-title>International uniform response criteria for multiple myeloma</article-title>. <source xml:lang="en">Leukeimia</source>. <year>2004</year>;<volume>20</volume>:<fpage>1467</fpage>&#x02010;<lpage>1473</lpage>.</mixed-citation></ref><ref id="cas13550-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cas13550-cit-0028">
<string-name>
<surname>Simon</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wittes</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Ellenberg</surname>
<given-names>SS</given-names>
</string-name>. <article-title>Randomized phase II clinical trials</article-title>. <source xml:lang="en">Cancer Treat Rep</source>. <year>1985</year>;<volume>69</volume>:<fpage>1375</fpage>&#x02010;<lpage>1381</lpage>.<pub-id pub-id-type="pmid">4075313</pub-id></mixed-citation></ref><ref id="cas13550-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cas13550-cit-0029">
<string-name>
<surname>Kaplan</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Meier</surname>
<given-names>P</given-names>
</string-name>. <article-title>Nonparametric estimation from incomplete observations</article-title>. <source xml:lang="en">J Am Stat Assoc</source>. <year>1958</year>;<volume>53</volume>:<fpage>457</fpage>&#x02010;<lpage>481</lpage>.</mixed-citation></ref><ref id="cas13550-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cas13550-cit-0030">
<string-name>
<surname>Rajkumar</surname>
<given-names>SV</given-names>
</string-name>. <article-title>CME information: multiple myeloma: 2016 update on diagnosis, risk&#x02010;stratification and management</article-title>. <source xml:lang="en">Am J Hematol</source>. <year>2016</year>;<volume>91</volume>:<fpage>719</fpage>&#x02010;<lpage>734</lpage>.<pub-id pub-id-type="pmid">27291302</pub-id></mixed-citation></ref><ref id="cas13550-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cas13550-cit-0031">
<string-name>
<surname>Sonneveld</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Avet&#x02010;Loiseau</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lonial</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Treatment of multiple myeloma with high&#x02010;risk cytogenetics: a consensus of the International Myeloma Working Group</article-title>. <source xml:lang="en">Blood</source>. <year>2016</year>;<volume>127</volume>:<fpage>2955</fpage>&#x02010;<lpage>2962</lpage>.<pub-id pub-id-type="pmid">27002115</pub-id></mixed-citation></ref><ref id="cas13550-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cas13550-cit-0032">
<string-name>
<surname>Tajima</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Uranishi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Iida</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Komatsu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nitta</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ueda</surname>
<given-names>R</given-names>
</string-name>. <article-title>Global real&#x02010;time quantification/reverse transcription&#x02010;polymerase chain reaction detecting protooncogenes associated with 14q32 chromosomal translocation in multiple myeloma</article-title>. <source xml:lang="en">Haematologica</source>. <year>2005</year>;<volume>90</volume>:<fpage>559</fpage>&#x02010;<lpage>562</lpage>.<pub-id pub-id-type="pmid">15820958</pub-id></mixed-citation></ref><ref id="cas13550-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cas13550-cit-0033">
<string-name>
<surname>Inagaki</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tajima</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Uranishi</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Global real&#x02010;time quantitative reverse transcription&#x02010;polymerase chain reaction detecting proto&#x02010;oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma</article-title>. <source xml:lang="en">Leuk Res</source>. <year>2013</year>;<volume>37</volume>:<fpage>1648</fpage>&#x02010;<lpage>1655</lpage>.<pub-id pub-id-type="pmid">24210217</pub-id></mixed-citation></ref><ref id="cas13550-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cas13550-cit-0034">
<string-name>
<surname>San Miguel</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Schlag</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Khuageva</surname>
<given-names>NK</given-names>
</string-name>, et&#x000a0;al. <article-title>Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2008</year>;<volume>359</volume>:<fpage>906</fpage>&#x02010;<lpage>917</lpage>.<pub-id pub-id-type="pmid">18753647</pub-id></mixed-citation></ref><ref id="cas13550-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cas13550-cit-0035">
<string-name>
<surname>Ogawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Suzuki</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sakai</surname>
<given-names>A</given-names>
</string-name>, et&#x000a0;al. <article-title>Phase I/II study of bortezomib &#x02010; melphalan &#x02010; prednisolone for previously untreated Japanese patients with multiple myeloma</article-title>. <source xml:lang="en">Cancer Sci</source>. <year>2013</year>;<volume>104</volume>:<fpage>912</fpage>&#x02010;<lpage>919</lpage>.<pub-id pub-id-type="pmid">23574271</pub-id></mixed-citation></ref><ref id="cas13550-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cas13550-cit-0036">
<string-name>
<surname>Guglielmelli</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Petrucci</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Saglio</surname>
<given-names>G</given-names>
</string-name>, et&#x000a0;al. <article-title>Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients</article-title>. <source xml:lang="en">Br J Haematol</source>. <year>2010</year>;<volume>152</volume>:<fpage>108</fpage>&#x02010;<lpage>110</lpage>.<pub-id pub-id-type="pmid">21083653</pub-id></mixed-citation></ref><ref id="cas13550-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cas13550-cit-0037">
<string-name>
<surname>Harousseau</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Attal</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Avet&#x02010;Loiseau</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem&#x02010;cell transplantation in newly diagnosed multiple myeloma: results of the IFM2005&#x02010;01 phase III trial</article-title>. <source xml:lang="en">J Clin Oncol</source>. <year>2010</year>;<volume>28</volume>:<fpage>4621</fpage>&#x02010;<lpage>4629</lpage>.<pub-id pub-id-type="pmid">20823406</pub-id></mixed-citation></ref><ref id="cas13550-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cas13550-cit-0038">
<string-name>
<surname>San Miguel</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Weisel</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Moreau</surname>
<given-names>P</given-names>
</string-name>, et&#x000a0;al. <article-title>Pomalidomide plus low&#x02010;dose dexamethasone versus high&#x02010;dose dexamethasone alone for patients with relapsed and refractory multiple myeloa (MM&#x02010;003): a randomized, open&#x02010;label, phase 3 trial</article-title>. <source xml:lang="en">Lancet Oncol</source>. <year>2013</year>;<volume>14</volume>:<fpage>1055</fpage>&#x02010;<lpage>1066</lpage>.<pub-id pub-id-type="pmid">24007748</pub-id></mixed-citation></ref><ref id="cas13550-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cas13550-cit-0039">
<string-name>
<surname>Van Beurden&#x02010;Tan</surname>
<given-names>CHY</given-names>
</string-name>, <string-name>
<surname>Franken</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Blommestein</surname>
<given-names>HM</given-names>
</string-name>, et&#x000a0;al. <article-title>Systematic literature review and network meta&#x02010;analysis of treatment outcomes in relapsed and/or refractory multiple myeloma</article-title>. <source xml:lang="en">J Clin Oncol</source>. <year>2017</year>;<volume>35</volume>:<fpage>1312</fpage>&#x02010;<lpage>1319</lpage>.<pub-id pub-id-type="pmid">28240968</pub-id></mixed-citation></ref><ref id="cas13550-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cas13550-cit-0040">
<string-name>
<surname>Hjorth</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hjertner</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Meldgaard</surname>
<given-names>L</given-names>
</string-name>, et&#x000a0;al. <article-title>Thalidomide and dexamethasone vs bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study</article-title>. <source xml:lang="en">Eur J Haematol</source>. <year>2012</year>;<volume>88</volume>:<fpage>485</fpage>&#x02010;<lpage>496</lpage>.<pub-id pub-id-type="pmid">22404182</pub-id></mixed-citation></ref><ref id="cas13550-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="cas13550-cit-0041">
<string-name>
<surname>Moreau</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pylypenko</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Grosicki</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non&#x02010;inferiority study</article-title>. <source xml:lang="en">Lancet Oncol</source>. <year>2011</year>;<volume>12</volume>:<fpage>431</fpage>&#x02010;<lpage>440</lpage>.<pub-id pub-id-type="pmid">21507715</pub-id></mixed-citation></ref></ref-list></back></article>